Gainers

• Addex Therapeutics (NASDAQ:ADXN) stock moved upwards by 73.5% to $5.01 during Thursday's regular session.
• enGene Therapeutics (NASDAQ:ENGN) stock rose 29.37% to $2.33. The company's market cap stands at $120.6 million.
• Bristol-Myers Squibb Company Celegne Contingent Value Rights (NYSE:CELGR) stock moved upwards by 28.57% to $0.18.
• QTREX Quantum (NASDAQ:QTEX) shares increased by 18.57% to $1.17. The company's market cap stands at $65.9 million.
• Traws Pharma (NASDAQ:TRAW) stock increased by 17.95% to $0.29. The market value of their outstanding shares is at $3.8 million.
• Cumberland Pharma (NASDAQ:CPIX) stock rose 17.48% to $7.19. The market value of their outstanding shares is at $91.6 million. As per the news, the Q3 earnings report came out 2 days ago.

Losers

• Estrella Immunopharma (NASDAQ:ESLA) stock decreased by 45.0% to $0.44 during Thursday's regular session. The company's market cap stands at $34.5 million.
• SeaStar Medical Holding (NASDAQ:ICU) shares decreased by 41.67% to $1.12. The market value of their outstanding shares is at $10.2 million. As per the press release, Q3 earnings came out yesterday.
• Jin Medical International (NASDAQ:ZJYL) shares fell 31.38% to $3.37. The company's market cap stands at $38.4 million.
• electroCore (NASDAQ:ECOR) stock declined by 28.28% to $5.53. The market value of their outstanding shares is at $69.5 million.
• Tessera Defense (AMEX:HLSQ) shares fell 27.95% to $0.03.
• OptimizeRx (NASDAQ:OPRX) stock declined by 18.83% to $7.26. The market value of their outstanding shares is at $165.5 million. As per the news, the Q3 earnings report came out yesterday. See Also: www.benzinga.com/money/best-healthcare-stocks/

This article was generated by Benzinga's automated content engine and reviewed by an editor.

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.